Lobular panniculitis after subcutaneous administration of interleukin-2 (IL-2), and its exacerbation during intravenous therapy with IL-2.
Interleukin-2 (IL-2) is now registered for the treatment of renal cell carcinoma in a number of European countries. The subcutaneous (sc) route of administration is being used increasingly because of its better toxicity profile compared with higher dose intravenous (iv) protocols. We report here a patient who developed a lobular panniculitis at the site of sc IL-2 injection which prevents continuation of sc therapy. Subsequent administration of the same IL-2 dose by iv injection caused recurrence of the problem again necessitating discontinuation of IL-2 treatment.
Baars
J W
JW
Department of Medical Oncology, Free University Hospital, Amsterdam, The Netherlands.
Coenen
J L
JL
Wagstaff
J
J
van der Valk
P
P
Pinedo
H M
HM
D000328:Adult; D001706:Biopsy; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000628:therapy; D015434:Panniculitis / Q000139:chemically induced* / Q000473:pathology; D012008:Recurrence; D012867:Skin / Q000473:pathology
D007376:Interleukin-2